FDA inspection
Luoxin Aurovitas Pharma Chengdu Co Ltd: FDA inspection ending Aug 11, 2023
FDA inspection 1218133 · Voluntary Action Indicated (VAI) · Chengdu
Key facts
| Inspection ID | 1218133 |
|---|---|
| Firm | Luoxin Aurovitas Pharma Chengdu Co Ltd |
| FEI number | 3019967180 |
| Address | No. 800 Haifa Road, Wenjiang |
| City | Chengdu |
| Fiscal year | 2023 |
| Inspection end date | Aug 11, 2023 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data